Clinical Trials

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06284122 2026-06-05

MorningLyte

790 enrolled

Lymphoma, Follicular

NCT06765317 2026-06-05

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04722172 2026-06-04

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06943872 2026-06-04

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06084936 2026-06-03

GLOBRYTE

182 enrolled

Lymphoma

NCT06624085 2026-06-03

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

50 enrolled

Lymphoma

NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07003295 2026-06-03

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Phase 2 Not yet recruiting

Lymphoma, Mantle-Cell

NCT07624799 2026-06-03

PACIFIC

82 enrolled

Leukemia, B-Cell

NCT06191744 2026-06-02

EPCORE™FL-2

1,095 enrolled

Phase 1 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04739813 2026-06-01

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

34 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05929222 2026-06-01

FIL_GAZEBO

190 enrolled

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT06073821 2026-06-01

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03269669 2026-05-29

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT03701282 2026-05-29

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

465 enrolled 11 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04077723 2026-05-29

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

Lymphoma, Non-Hodgkin

NCT05100862 2026-05-27

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Phase 1 Active not recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04277637 2026-05-22

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

437 enrolled

Mature B-Cell Malignancies

NCT04269902 2026-05-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05057494 2026-05-19

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06849713 2026-05-19

BOSon

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

121 enrolled

Lymphoma, Non-Hodgkin

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06867536 2026-05-15

GLOHRT-01

40 enrolled